SCHEMBL24809783

SCHEMBL24809783

CN(C)Cc1cccc(-c2cn(C(=O)NCCc3ccccc3)cn2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 1/20 0.43
ALDH1A1 P00352 4/20 0.41
SMN1; SMN2 Q16637 3/20 0.41
HPGD P15428 1/20 0.41
AOC3 Q16853 1/20 0.40
TAAR1 Q96RJ0 1/20 0.39
HIF1A Q16665 1/20 0.39
EGFR P00533 1/20 0.39
NMT1 P30419 1/20 0.39
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
TP53 P04637 2/20 0.38
HDAC1 Q13547 1/20 0.38
RAB9A P51151 3/20 0.38
NPC1 O15118 2/20 0.38
P2RX4 Q99571 1/20 0.38
KDM4E B2RXH2 1/20 0.38
POLB P06746 1/20 0.38
APOBEC3A P31941 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23132278 0.90 MCHR1 (0.45) FAAHALDH1A1TAAR1HIF1ATP53
SCHEMBL24809696 0.89 FAAH (0.39) FAAHALDH1A1SMN1; SMN2HPGDHIF1A
SCHEMBL29817652 0.89 FAAH (0.39) FAAHALDH1A1SMN1; SMN2HPGDHIF1A
SCHEMBL24809404 0.86 ALDH1A1 (0.47) FAAHALDH1A1SMN1; SMN2HPGDTAAR1
SCHEMBL24810551 0.84 KDM4E (0.38) ALDH1A1SMN1; SMN2HPGDTAAR1TP53
SCHEMBL29817737 0.80 CYP2C9 (0.54) ALDH1A1SMN1; SMN2HIF1ARAB9ANPC1
SCHEMBL24811030 0.80 CYP2C9 (0.54) ALDH1A1SMN1; SMN2HIF1ARAB9ANPC1
SCHEMBL24810703 0.80 RAB9A (0.51) ALDH1A1SMN1; SMN2HIF1ARAB9ANPC1
SCHEMBL24809675 0.79 ASAH1 (0.50) FAAHHPGDRAB9ANPC1
SCHEMBL24809408 0.79 HIF1A (0.46) ALDH1A1SMN1; SMN2HPGDHIF1AAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2022-12-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220411388-A1 SUBSTITUTED IMIDAZOLE CARBOXAMIDES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, CLN6 FAAH 368/4885ALDH1A1 1398/4885SMN1; SMN2 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.